Frontiers in Psychiatry
December 2, 2021
Maria Gałuszko‐węgielnik, Adam Włodarczyk, Wiesław Jerzy Cubała et al.
5 citations
Purpose: Approximately 30% of patients with major depressive disorder (MDD) are treatment resistant. There is an unquestionable need for new treatment strategies. Subanesthetic doses of intravenous (IV) ketamine have a rapid antidepressant effect in treatment-resistant depression (TRD). This paper describes the efficacy of repeated series of intravenous ketamine infusions as an add-on treatment...
Journal of Affective Disorders
December 1, 2021
Annabella Hochschild, John G Keilp, Sean P Madden et al.
Objective: Studies demonstrate rapid antidepressant and anti-suicidal ideation effects of subanesthetic ketamine. The specific subcomponents of depression that are most closely tied to reduction of suicidal ideation with ketamine treatment are less explored. Methods: Exploratory, post hoc analysis of data from a randomized clinical trial of ketamine vs midazolam in patients with major...
Journal of Affective Disorders
December 1, 2021
Wei Zheng, Lingna Gu, Chen-Hui Sun et al.
OBJECTIVES Anhedonia is a common, persistent, and disabling phenomenon in patients with major depressive disorder (MDD) and bipolar depression (BD). This study was conducted to investigate the comparative effectiveness of repeated ketamine infusions in treating anhedonia in Chinese individuals suffering from MDD and BD. METHODS Ninety-seven individuals suffering from MDD (n=77) or BD (n=20)...
Neuropsychopharmacology
November 27, 2021
Marijn Lijffijt, Nicholas Murphy, Sidra Iqbal et al.
Evidence supporting specific therapies for late-life treatment-resistant depression (LL-TRD) is necessary. This study used Bayesian adaptive randomization to determine the optimal dose for the probability of treatment response (≥50% improvement from baseline on the Montgomery-Åsberg Depression Rating Scale) 7 days after a 40 min intravenous (IV) infusion of ketamine 0.1 mg/kg (KET 0.1), 0.25...
Translational Psychiatry
November 25, 2021
Blair J. Price, Brooke Morath, Mayo Clinic et al.
Lithium, a mood stabilizer and common adjunctive treatment for refractory depression, shares overlapping mechanisms of action with ketamine and enhances the duration of ketamine’s antidepressant actions in rodent models at sub-therapeutic doses. Yet, in a recent clinical trial, lithium co-treatment with ketamine failed to improve antidepressant outcomes in subjects previously shown to respond...
Frontiers in Psychiatry
November 24, 2021
Sherry-Anne Muscat, Glenn Hartelius, Courtenay Richards Crouch et al.
47 citations
Research over the last two decades has established ketamine as a safe, effective, fast-acting, and sustained antidepressant that significantly reduces adverse symptoms associated with depression, even in patients who are treatment resistant. Much of this research has evolved within the framework of several independent branches of scientific inquiry: in addition to the study of ketamine is a...
Nutrients
November 20, 2021
Johanna Louise Keeler, Janet Treasure, Mario F Juruena et al.
55 citations
Anorexia nervosa (AN) is a highly complex disorder to treat, especially in severe and enduring cases. Whilst the precise aetiology of the disorder is uncertain, malnutrition and weight loss can contribute to reductions in grey and white matter of the brain, impairments in neuroplasticity and neurogenesis and difficulties with cognitive flexibility, memory and learning. Depression is highly...
Scholarly Research In Progress
November 8, 2021
Sankung X. Darboe, Peter J. Koszuta, Paul W. Lee et al.
The anesthetic agent ketamine has been under investigation as a potential antidepressant for two decades. Animal studies and subsequent randomized control trials for patients have provided extensive evidence of ketamine’s rapid antidepressant outcomes both structurally at the receptor level as well as behaviorally. A review of current literature hones in on the putative rapid mechanisms of...
Life
November 5, 2021
Mateusz Kowalczyk, Edward Kowalczyk, Paweł Kwiatkowski et al.
16 citations
The SARS-CoV-2 coronavirus epidemic has led to an increase in the number of people with depression. Symptoms related to the mental sphere (mainly depression and anxiety) may be experienced by one third of the worldwide population. This entails the need for the effective and rapid treatment of depressive episodes. An effective drug seems to be s-ketamine, which was accepted in March 2019 by the...
Brain, Behavior, & Immunity - Health
November 1, 2021
N. Nikkheslat
67 citations
Major depressive disorder (MDD) is a common psychiatric disorder with multifactorial aetiology and complex pathophysiology. Despite availability of various pharmacological and non-pharmacological therapeutic strategies, treatment resistant depression (TRD) remains a significant challenge with specific concern for those patients with severe depressive symptoms in particular suicidal ideations...